Polycystic ovary syndrome

2020 ◽  
pp. 528-535
Author(s):  
Zhongwei Huang ◽  
Eu Leong Yong
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Endometrial Hyperplasia ◽  
Polycystic Ovary ◽  
Reproductive Age ◽  
Endocrine Disorders ◽  
Age Group ◽  
Ovary Syndrome ◽  
Reproductive Ageing ◽  
Reproductive Age Group

Polycystic ovary syndrome (PCOS) is an enigmatic condition and its pathophysiology remains to be determined but it is likely to involve the androgen, insulin, and anti-Mullerian hormone pathways. PCOS is diagnosed in women in the reproductive age group based on the Rotterdam criteria. The spectrum of disease involves various phenotypes based on the current diagnostic criteria and this may have reproductive, metabolic, and endocrine consequences. Reproductive issues include that of irregular menstrual cycles and anovulation. Metabolic disorders such as insulin resistance, obesity, dyslipidaemia, and hypertension must be screened for in all women who are diagnosed with PCOS. Long-term risks of metabolic and endocrine disorders in women with PCOS still need further confirmation with more robust data. Reproductive ageing appears to be increased in women with PCOS and they seem to menopause at a later age. Thus far, PCOS appears to be associated with endometrial hyperplasia and cancer.

scholarly journals Incidence and risk factors of polycystic ovary syndrome among women in reproductive age group attending a tertiary health care hospital in Western Maharashtra

2019 ◽  
Vol 8 (7) ◽  
pp. 2804
Author(s):  
Khushboo Suresh Shinde ◽  
Sunil Somnath Patil
Keyword(s):  
Risk Factors ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Early Stage ◽  
Reproductive Age ◽  
Care Hospital ◽  
Age Group ◽  
Ovary Syndrome ◽  
Study Population ◽  
Reproductive Age Group

Background: Polycystic Ovary Syndrome (PCOS) is an endocrine disorder affecting women of reproductive age group. Though its incidence is markedly increasing, the awareness is still low; as a result it remains undiagnosed. Aim of this study was to find the incidence and risk factors of PCOS among women in reproductive age group, so as to encourage young women to seek timely treatment and prevent its long term complications.Methods: A study was conducted over a period of 1 year amongst 100 women attending the Gynecology OPD using a paper based questionnaire. General examination and the required laboratory tests were done to confirm the diagnosis.Results: It was found that the incidence of PCOS among the study population was 21%. Risk factors include lack of physical activity, irregular menstrual cycle, body mass index more than 25, and Waist-hip ratio above 0.86.Conclusions: It is seen that there is a need to educate women at an early stage to prevent the development of this syndrome and its early detection by them. This will facilitate the health professionals to start the treatment at a stage where the complications have not yet set in.

Health Care-Related Economic Burden of Polycystic Ovary Syndrome in the United States: Pregnancy-Related and Long-Term Health Consequences

2021 ◽  
Author(s):  
Carrie Riestenberg ◽  
Anika Jagasia ◽  
Daniela Markovic ◽  
Richard P Buyalos ◽  
Ricardo Azziz
Keyword(s):  
United States ◽  
Polycystic Ovary Syndrome ◽  
Economic Burden ◽  
Polycystic Ovary ◽  
The United States ◽  
Reproductive Age ◽  
Cochrane Library ◽  
Control Group ◽  
Ovary Syndrome

Abstract Context Polycystic ovary syndrome (PCOS) is the most common endocrine disorder of reproductive-aged women, affecting approximately 5-20% of women of reproductive age. A previous estimate noted that the economic burden of PCOS approximates $3.7 billion annually in 2020 USD when considering only the costs of the initial diagnosis and of reproductive endocrine morbidities, not considering the costs of pregnancy-related and long-term morbidities. Objective To estimate the excess prevalence and economic burden of pregnancy-related and long-term health morbidities attributable to PCOS. Data Sources PubMed, EmBase and Cochrane Library. Study Selection Studies in which the diagnosis of PCOS was consistent with the Rotterdam, National Institutes of Health (NIH), or Androgen Excess & PCOS (AE-PCOS) Society criteria, or that used electronic medical record diagnosis codes, or diagnosis based on histopathologic sampling were eligible for inclusion. Studies that included an outcome of interest and a control group of non-PCOS patients who were matched or controlled for body mass index (BMI) were included. Data Extraction Two investigators working independently extracted data on study characteristics and outcomes. Data Synthesis Data was pooled using random-effects meta-analysis. The I 2statistic was used to assess inter-study heterogeneity. The quality of selected studies was assessed using the Newcastle-Ottawa Scale. Results The additional total healthcare-related economic burden due to pregnancy-related and long-term morbidities associated with PCOS in the United States is estimated to be $4.3 billion annually in 2020 USD. Conclusions Together with our prior analysis, the economic burden of PCOS is estimated at $8 billion annually in 2020 USD.

scholarly journals Simultaneous alterations in ovaries and bone as a result of Polycystic Ovary Syndrome

2021 ◽  
Vol 3 (2) ◽  
pp. 2-14
Author(s):  
Ana Lúcia de Oliveira Bonfá ◽  
Eduardo Donato Alves ◽  
Víctor Fabrício ◽  
Keico Okino Nonaka ◽  
Janete Aparecida Anselmo-Franci ◽  
...  
Keyword(s):  
Cell Culture ◽  
Animal Model ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Reproductive Age ◽  
Estradiol Valerate ◽  
Endocrine Disorders ◽  
Ovary Syndrome ◽  
Bone Properties ◽  
In Vivo Animal Model

Polycystic ovary syndrome (PCOS) is one of the most widely recognized endocrine disorders affecting reproductive-age women. The etiopathogenesis and mechanisms of this syndrome remain unclear. Diagnosis requires two of the following: polycystic ovaries, oligo- or anovulation, and hyperandrogenism. Most women with PCOS display conditions such as metabolic abnormalities, diabetes, obesity, cardiovascular disease, and/or bone dysfunction. Considering the ethical limitations of human studies, animal and cell culture models that reflect some features of PCOS are important for investigation of this syndrome. The aim of the present work was to study some of the endocrine relationships between ovaries and bone tissue in a polycystic ovary syndrome animal model. The study was performed using an estradiol valerate PCOS-induced rat model (n = 30) and bone mesenchymal stem cell cultured from bone marrow of those animals. It was hypothesized that changes of the endocrine relationship between ovaries and bones could be observed in from in vivo animal model and in vitro cell culture assays. The ovarian morphological and endocrine changes seem to be correlated with endocrine, biophysical, and biomechanical changes in bone properties. Mesenchymal stem cells obtained from PCOS-induced rats, cultured for up to 21 days and differentiated into osteoblasts, presented lower viability and reduced mineralization of the extracellular matrix. Taken together, these results indicate important endocrine and structural effects of PCOS in ovaries and bones, contributing to part of the understanding of the pathophysiological mechanisms of PCOS.

scholarly journals Clinical Evaluation of Standardized Fenugreek Seed Extract as Furostanolic Saponins (Furocyst) In Polycystic Ovary Syndrome Patients

2018 ◽  
Vol 2 (1) ◽  
Keyword(s):  
Polycystic Ovary ◽  
Seed Extract ◽  
Reproductive Age ◽  
Age Group ◽  
Women Of Reproductive Age ◽  
Ovary Syndrome ◽  
Fenugreek Seed ◽  
Function Test ◽  
Study Population ◽  
Reproductive Age Group

Background: Polycystic Ovarian Syndrome (PCOS) is one of the most common endocrine conditions affecting women of reproductive age Group with prevalence of approximately 7- 10% worldwide. Objective: The objectives of the study were to find out the effect of Standardized Fenugreek Seed extract as Furostenolic Saponins (Furocyst) on reduction in ovarian volume and the number of ovarian cysts. Method: An open labelled, Multicentre, single-arm, and non-comparative study was planned on 50 female patients suffering from PCOS. Patients were enrolled as per inclusion i.e. premenopausal women between 18-45 years of age, BMI less than 42, diagnosed with PCOS, with adequate hepatic, renal and haematological functions. Patients willing to give informed consent in writing Patients with Hysterectomy/ Congenital adrenal Hyperplasia/ Cushing’s syndrome / Androgen secreting tumour/ Thyroid-dysfunction/ Hypo-gonadism were excluded. Women were allocated to receive Furocyst and were assessed on parameters of USG & hormonal on second day of cycle before and every 4 weeks within treatment period of 12 weeks. Result: After treatment for 3 months with Furocyst caused significant reduction in ovary Volume (p 0.000), 46% of study population showed reduction in cyst size who had bigger cyst, 36% study population showed complete dissolution of cyst who had small cyst, 12% study population got pregnant and 71% patients reported regular menstrual cycle on completion of treatment and LH: FSH ratio was also reduced to normal. Overall 94% of patients reported positively or got benefitted from Standardized Fenugreek seed extract dosing. No changes were observed in liver function test (LFT), kidney function test (KFT) and haemogram level. Conclusions: Present Study indicates that Standardized Fenugreek seed extract as Furostenolic Saponins (Furocyst) is very effective and safe in the management of Poly Cystic Ovary Syndrome in women of reproductive age Group.

scholarly journals Clinical features of polycystic ovary syndrome phenotypes in women with normogonadotropic anovulation in reproductive age

2019 ◽  
Vol 68 (3) ◽  
pp. 7-14
Author(s):  
Elena I. Abashova ◽  
Maria A. Shalina ◽  
Elena V. Misharina ◽  
Natalia N. Tkachenko ◽  
Olga L. Bulgakova
Keyword(s):  
Menstrual Cycle ◽  
Polycystic Ovary Syndrome ◽  
Carbohydrate Metabolism ◽  
Clinical Features ◽  
Endometrial Hyperplasia ◽  
Polycystic Ovary ◽  
Reproductive Age ◽  
Women Of Reproductive Age ◽  
Ovary Syndrome ◽  
Chronic Endometritis

Hypothesis/aims of study. Polycystic ovary syndrome (PCOS) is a common disease, the frequency of which ranges from 8 to 13% in women of reproductive age. PCOS is a complex polygenic endocrine disorder with reproductive, metabolic, and psychological features. Currently, four PCOS phenotypes are identified that are associated with metabolic disorders, insulin resistance, impaired glucose tolerance (IGT), diabetes mellitus, and an increase in the number of risk factors for cardiovascular diseases. The aim of this study was to investigate the clinical features of PCOS phenotypes in women with normogonadotropic anovulation in reproductive age. Study design, materials, and methods. The study included 60 women of reproductive age from 24 to 37 years (mean age 28 ± 4 years) with PCOS and normogogonadotropic, normoprolactinemic anovulation. We studied the levels of anti-mullerian, follicle-stimulating, luteinizing hormone, prolactin, estradiol, and androgens from days 2 to 5 of the menstrual cycle. The serum progesterone level was studied by ELISA using test systems manufactured by Alkor Bio Ltd. (Russia) on days 20–23 of the menstrual cycle for three consecutive cycles. The average level of progesterone in the blood on days 20–23 of the menstrual cycle was 3.1 ± 1.5 nM. Echographic methods for diagnosing polycystic ovaries were used. All women included in the study underwent hysteroscopy on days 18–22 of the menstrual cycle, followed by a histological and immunohistochemical study of the endometrium. Results. In women with anovulatory PCOS phenotypes, phenotype A (classical) was detected in 32 (53.3%) women; phenotype B (anovulatory) in 18 (30%) women; phenotype D (non-androgenic) in 10 (16.7%) women with. In 32 (53.3%) patients, changes in carbohydrate metabolism (IGT) were found. Clinical and biochemical manifestations of androgen-dependent dermopathy (acne, oily seborrhea, and hirsutism) were significantly (p < 0.05) more often observed in PCOS patients with phenotypes A (84.4%) and B (88.9%) than in women with phenotype D (30%). In the majority (93.8%) of patients with IGT, the androgenic-anovulatory PCOS phenotypes were detected: phenotype A in 20 (62.5%) women and phenotype B in 10 (31.3%) women. Phenotype D (non-androgenic) was present only in two women with PCOS and IGT. As a result of complex histological and immunohistochemical studies of endometrial biopsy specimens, chronic endometritis was detected in 44 (73.3%) examined women with PCOS and simple glandular endometrial hyperplasia was diagnosed in 13 (21.7%) PCOS patients. The incidence of chronic endometritis and simple glandular endometrial hyperplasia in women with normogonadotropic anovulation and PCOS directly depended (r = 0.35; p < 0.05) on disorders of carbohydrate metabolism and was detected more often in patients with PCOS and IGT. Conclusion. The differential approach to the examination of patients with various PCOS phenotypes allows personalizing the therapy of this disease and determining the complex of preventive measures to improve the quality of life of women of reproductive age.

scholarly journals Depression Due to Polycystic Ovary Syndrome in Adolescents

2021 ◽  
pp. 224-227
Author(s):  
Pratheek R. Kashyap ◽  
Rakesh Kumar Jha ◽  
Praful Patil
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Psychological Health ◽  
Polycystic Ovary ◽  
Self Esteem ◽  
Reproductive Age ◽  
Future Research ◽  
Ovary Syndrome ◽  
Small Cyst ◽  
Psychiatric Issues

Introduction: Polycystic ovary syndrome(PCOS) is a common endocrinal disorder of reproductive age, that cause enlarged ovaries with small cyst on the outer edges with infrequent or prolonged menstrual cycles, excess hair growth, acne and obesity, which is nowadays prevailing among females at adolescent stage. About 5-10% of women among the general population of in the world are affected by PCOS. There is an increase in the prevalence of PCOS among the women and young girls of reproductive age, where they experience depression because of PCOS particularly. The exact cause of PCOS is unknown. The early diagnosis and treatment along with weight loss may reduce the long term complications of PCOS. It is not only a problem associated with reproduction, but also has associated vital metabolic and psychological health risks. Aim: Depression Due to Polycystic Ovary Syndrome in Adolescents Conclusion: In comparison to safe controls, adolescents with PCOS had lower self-esteem, more anxiety, and more depressive symptoms. Future research is required to look into the psychiatric issues that affect adolescents with PCOS.

scholarly journals Polycystic Ovary Syndrome in Adolescence

2019 ◽  
Vol 7 (10) ◽  
pp. 101 ◽  
Author(s):  
Deans
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Management Strategies ◽  
Signs And Symptoms ◽  
Endocrine Disorders ◽  
Lifestyle Modifications ◽  
Ovary Syndrome ◽  
Early Management ◽  
Ovarian Morphology

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in females, and is characterized by ovulatory dysfunction, hyperandrogenism, and polycystic ovarian morphology based on ultrasound. Controversy surrounds the optimum diagnosis and management in the adolescent population. Many patients with adult PCOS present with pathognomonic symptoms as adolescents, and there is value in early diagnosis due to the associated long-term metabolic and reproductive health sequalae. A definitive diagnosis does not need to be made prior to implementing treatment in this group of young women. The practitioner who has an adolescent presenting with signs and symptoms of PCOS, has a unique opportunity to risk stratify, screen for co-morbidities, and implement early management strategies, many of which are lifestyle modifications, to help prevent long term morbidity associated with this disease.

scholarly journals A Prospective Study of the Prevalence of the Polycystic Ovary Syndrome in Unselected Caucasian Women from Spain1

2000 ◽  
Vol 85 (7) ◽  
pp. 2434-2438 ◽  
Author(s):  
Miryam Asunción ◽  
Rosa M. Calvo ◽  
José L. San Millán ◽  
José Sancho ◽  
Sergio Avila ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Blood Donation ◽  
Polycystic Ovary ◽  
Reproductive Age ◽  
Endocrine Disorders ◽  
Androgenic Alopecia ◽  
Hydroxylase Deficiency ◽  
Ovary Syndrome ◽  
Caucasian Women ◽  
21 Hydroxylase Deficiency

We prospectively estimated the prevalence of the polycystic ovary syndrome (PCOS), as defined by the NIH/NICHHD 1990 endocrine criteria, in a population of 154 Caucasian women of reproductive age reporting spontaneously for blood donation. Anthropometric data; the presence of hirsutism, acne, and androgenic alopecia; and the menstrual history were recorded by a single investigator. In 145 women, blood samples were also obtained for measurement of serum androgen levels. PCOS was defined by the presence of 1) oligomenorrhea, 2) clinical and/or biochemical hyperandrogenism, and 3) exclusion of hyperprolactinemia, thyroid disorders, and nonclassic 21-hydroxylase deficiency. Hirsutism was defined by a modified Ferriman- Gallwey score of 8 or more, acne was considered as a sign of hyperandrogenism when persistent after the second decade of life, and hyperandrogenemia was defined by an increase in circulating testosterone or dehydroepiandrosterone sulfate or an increase in the free androgen index above the 95th percentile of the control values derived from the nonhirsute, nonacneic women having regular menses who were not receiving hormonal therapy. PCOS was present in 10 (6.5%), hirsutism was present in 11 (7.1%), and acne was present in 19 (12.3%) of the 154 women. Our results demonstrate a 6.5% prevalence of PCOS, as defined, in a minimally biased population of Caucasian women from Spain. The polycystic ovary syndrome, hirsutism, and acne are common endocrine disorders in women.

scholarly journals Study the Effect of Interleukin36 Gamma and AMH in Iraqi Women with PCOS

2018 ◽  
Vol 28 (3) ◽  
pp. 151
Author(s):  
Wafa R. AlFatlawi
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Transforming Growth Factor ◽  
Seminal Fluid ◽  
Polycystic Ovary ◽  
Surrogate Marker ◽  
Reproductive Age ◽  
Endocrine Disorders ◽  
Ovary Syndrome ◽  
Markers Of Inflammation ◽  
Significant Difference

Polycystic ovary syndrome (PCOS) is one of the most common female endocrine disorders and affect approximately (5-10) % of women of reproductive age. Anti-Müllerian hormone (AMH) is a homodimeric glycoprotein, a member of the transforming growth factor-β superfamily, it is secreted exclusively from women by granulose cells of ovarian follicles and it is considered as the precise marker of follicle pool size. AMH has been shown to be a good surrogate marker for polycystic ovary syndrome (PCOS). Interleukins are considered as strong risk markers of inflammation. Interleukin-36 gamma (IL36) also known as interleukin-1 family member 9 (IL1F9) is a protein that in humans is encoded by the IL36G gene. Serum samples were collected on day 2 of the menstrual cycle. Serum IL36ɣ, FSH and LH concentration were measured by using ELISA. This study aimed to evaluate the association between IL36ɣ and AMH and study the relationship between obesity and AMH of women in the age of reproductive (25-35) yrs. This study included 28 infertile women with PCOS their husbands were apparently normal (hormones and seminal fluid analysis), their aged (25-35) years, and 20 healthy women aged (25-33) years as control. All control women & patients were from outpatients unit of Alkadumia teaching hospital at Baghdad and all the parameters were measured in Sigma Laboratory. Serum IL-36 ɣ elevated in PCOS patients mainly those with high AMH levels. This hormone increased in PCOS patients compared with control. There was a non-significant difference between patients and control to LH and FSH levels.

scholarly journals Analysis of the informativeness of melatonin evaluation in polycystic ovary syndrome

2016 ◽  
Vol 13 (4) ◽  
pp. 15-20 ◽  
Author(s):  
Elena Andreeva ◽  
Yulia Absatarova ◽  
Ekaterina Sheremetyeva ◽  
Dmitriy Derkatch ◽  
Tatiana Ponomareva ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Sleep Disorders ◽  
Polycystic Ovary ◽  
Reproductive Function ◽  
Reproductive Age ◽  
Control Group ◽  
Endocrine Disorders ◽  
Ovary Syndrome ◽  
Subjective Sleep ◽  
Pcos Group

Background. Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age. Recently, the role of melatonin in the pathogenesis of this syndrome became widely discussed among the scientists, because there is an evidence of its impact on the reproductive function and maturation of oocytes.Aim. To study a informativeness of melatonin determination and its relationship with sleep disorders in PCOS.Materials and methods. The study involved 120 women aged 17–35 years: 60 patients with PCOS and 60 women without this disorder as controls. The level of melatonin in the blood, saliva and its metabolite in urine – 6 sulfatoximelatonin were analyzed. To identify sleep disorders survey was conducted using a questionnaire scoring subjective sleep characteristics.Results. Sleep disorders based on subjective scoring profiles sleep characteristics were identified in PCOS group (up to 70% of patients) regardless of BMI. The level of 6-sulfatoximelatonin in urine, nocturnal melatonin levels in saliva (at 3:00 AM) and melatonin in the blood were significantly higher in patients with PCOS compared with the control group regardless of BMI. The level of melatonin in follicular fluid was lower in patients with PCOS. There was a significant correlation of melatonin levels in the blood and the degree of sleep disorders according to the questionnaire scoring subjective sleep characteristics, the level of melatonin in saliva at 3:00 AM and a 6-sulfatoximelatonin in daily urine (p = 0.046).Conclusions. PCOS is polyetiology disease, and an important role in the formation and progression in which plays melatonin. Correlation of levels of this hormone in different body fluids suggests its systemic action and direct involvement in the regulation of reproductive function.  

Sign in / Sign up

Export Citation Format

Share Document